Summary
Neoadjuvant chemotherapy (NACT) is now widely used in the management of locally advanced breast cancer and in patients with relatively large tumors who are interested in breast conservation. Patients who do not have a complete pathologic complete response typically have poorer outcomes compared with patients with a pCR [Rastogi P et al. J Clin Oncol 2008]. This article presents molecular profiling data on residual triple-negative breast cancer after NACT.
- Adjuvant/Neoadjuvant Therapy
- Oncology Genomics
- Oncology Clinical Trials
- Breast Cancer
- © 2013 MD Conference Express®
Tools
Profiling Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Targetable Genetic Alterations
Permalink:
Table of contents
Cited By...
- No citing articles found.